New York State spent at least $107 million on hepatitis C drugs during the third quarter of 2015, accounting for roughly 10 percent of all Medicaid drug spending.
That takes the total spent on hepatitis C drugs to more than $400 million through the first nine months of last year, emphasizing just how much strain the disease and a few other blockbuster drugs are putting on the state's insurance program for low-income residents.
The dollar figure may even be low as reporting to the federal government often lags.
Read Full Article »